Analytics of the Cost Effectiveness and Real-Time Health Risk Assessments for Pharmacy-Based Preventive Health Services

Chandni Sawlani[1], Pooja Sharma[2]

[1]*Assistant Professor, Department of CS & IT, Kalinga University, Raipur, India*
[2]*Research Scholar, Department of CS & IT, Kalinga University, Raipur, India*

KEYWORDS

Cost-Effectiveness Analysis, Health Risk Assessment, Pharmacy-based Preventive Health Services, Preventive Care

ABSTRACT

More patient-centered care and participation in managing chronic illnesses are features of the modern pharmacist's task, which has evolved substantially in recent years. Still, the issue of whether or not pharmacists are cost-effective in diabetes care persists. Cost-effectiveness analyses (CEA) have emerged as a crucial tool when making informed decisions about healthcare delivery. Patients' present health status, past medical history (personal and family), and lifestyle variables influencing their health are all part of a health risk assessment (HRA). Hence, this study proposed a Cost-Effectiveness Analysis of Pharmacy-based Preventive Health Services (CEA-PBPHS) model for real-time health risk assessment. Nowadays, medical professionals place a greater emphasis on preventative health care. This research aims to examine the potential impact of risk assessment tools on males past due for a physical examination and evaluate the return on investment (ROI) for community pharmacists who provide this service for free. More cost-efficient or cost-saving than conventional treatment is pharmacist engagement in diabetes management due to better glucose control, higher patient compliances, and lower risks of medication-related issues. The experimental outcomes demonstrate that the suggested CEA-PBPHS model increases the health risk assessment ratio by 98.9%, the personalized health service ratio by 97.5% and the cost-effectiveness analysis ratio by 98.3% compared to other existing models.

1. Introduction

Expanding the populace's right of entry to medical preventative remedies may be achieved through collaborations with different healthcare and public health specialists for the reason that network pharmacists are relatively on-hand healthcare experts [1]. To promote the health of a populace, community pharmacists may additionally offer clinical preventative offerings together with education, screenings, and referrals [2]. Primary prevention includes taking measures to make sure that an ailment does not expand, secondary prevention includes locating and treating signs and symptoms before they turn out to be severe, and tertiary prevention entails minimizing the severity of a sickness's outcomes once it has already manifested [21]. There are a variety of exclusive hints for how healthcare practitioners must interpret the statistics about the healing value of number one and secondary preventive programs, and the facts are occasionally contradictory [3]. Preventable risk elements still cause premature mortality and needless handicaps in older adults. Health danger assessment (HRA) is a fascinating approach for cost-effective fitness merchandising and preventive treatment in older adults, drawing upon a successful technique in running-age populations [17]. However, the technique's lengthy-term consequences stay uncertain [11]. The capacity to discover fitness issues at an early level, while they'll be simpler to treat or control, is a major benefit of preventative fitness reviews [4]. By identifying danger elements consisting of hypertension, high ldl cholesterol, or bizarre glucose stages, healthcare providers can intervene early with dietary and workout adjustments or pharmaceutical treatment plans to prevent the onset of persistent diseases like diabetes, cardiovascular ailment, or stroke [5].

Cost-effectiveness analysis (CEA) is a research methodology aimed at analyzing the overall costs and benefits of alternative therapies to manage disease in terms of systematic [18]. Clinical interventions have the potential to provide improved public health while reducing healthcare costs. Consequently, the cost of treatments can be justified by their design [7] .Patient outcomes are influenced by the pharmacist's level of participation, which in turn affects the intervention's economic value. If pharmacists are only partially involved in using technology, their digital treatments may not have the desired impact on patient outcomes [8]. Finally, it is acknowledged in the economic assessment framework that scheduling choices are often made with limited proof, particularly regarding patient

behaviour, the risk of adverse events, and potential benefits [19]. Inappropriate scheduling choices may lead to worse health outcomes and waste healthcare resources; thus it's crucial to prevent them. On the other hand, concerns about the reality are distinct from issues about the regulatory decision [10]. The main contribution of the paper is Designing the Cost-Effectiveness Analysis of Pharmacy-based Preventive Health Services (CEA-PBPHS) model for real-time health risk assessment. Evaluating the mathematical model of cost-effectiveness analysis for pharmacy-based health services. The results demonstrate that the suggested model increases health risk assessment, personalized health service ratio, and cost-effectiveness analysis compared to other models. The rest of the article is prearranged as follows: section 2 deliberates the related work, section 3 suggests the CEA-PBPHS model, section 4 deliberates the outcomes, and section 5 concludes the research paper.

2. Literature Review

A discrete choice experiment (DCE) was proposed by Gin Nie Chua et al. [20] to evaluate the potential future acceptance of a community pharmacy health checks. The DCE encompassed six characteristics, including service availability (wait, walk-in, or appointment only), service providers (pharmacist, trainee pharmacist, or nurse), check duration (30 or 45min), follow-up phone calls (yes, no, or within three months), and costs (comprised to measure the financial value of health check). Twelve multiple-choice tasks were developed using experimental design methodologies to describe various health check service [9]. A mixed logits (MXL) were utilized to examine the responses. A cost-utility analysis (CUA) for screening individuals at risk of type 2 diabetes via pharmacy was suggested by Kari Jalkanen et al. [12]. A decision-analytic model was established to determine the potential financial and health-related outcomes (concerning QALYs and costs) of a pharmacy-based service that screens and recruits individuals via pharmacies to contribute to digital lifestyle programs. The net monetary benefits (NMB) were used to evaluate the cost-effectiveness. On top of that, the social return on investments (SROI) was determined by dividing the intervention and recruiting expenses by the net present values of predicted savings. The time required to achieve the savings break-even point was called payback time. To evaluate minor health issues in community pharmacies, the decision tree-based triage (DTT) was suggested by Dominik Stampfli et al. [13]. We looked at client demographics, availability of general practitioners, suggested next steps, days of the week, and what would have happened if netCare hadn't been an option. The data from follow-up assessments was reviewed to alleviate symptoms and avoid the need for further treatments [6]. A second decision tree was needed to detect small health problems based on data from consultations when evaluation forms were left blank. An 84.7% resolution rates of minor health issues was achieved in Switzerland using pharmacist-led organized triaging services, indicating that pharmacists can decrease the demand on other primary health care provider. For primary care patients at risk of or living with chronic renal illness, Wubshet Tesfaye et al. [14] covered the cluster randomized trial protocol (CRTP) for screening and intervention led by pharmacists. Community pharmacy clusters will be randomly selected from adjacent zip codes. A total of 122 community pharmacies in both urban and rural regions will participate in the study. The study's primary outcomes are the rate variations in the number of drugs deemed difficult in kidney illness and the proportion of patients freshly diagnosed with chronic kidney disease (CKD) at the conclusion of the 12-month research time. Some of these drugs are nephrotoxic or given at dosages that aren't acceptable for the patient's renal function. To determine how vaccine assessment and patient counselling conducted by pharmacists in community pharmacies affected unmet immunization requirements, Ryan Lilly et al. [15] developed the vaccine assessment form (VAF) questionnaire. 133 people went to the pharmacy for vaccinations and filled out the VAF. Out of 126 unfulfilled immunization requirements, influenza and herpes zoster were the most prevalent, according to pharmacists. Most vaccination delays

were due to financial concerns, and referrals were the most prevalent result. According to the phi coefficients, there were statistically significant connections between referrals and unmet immunization requirements across all vaccine types.

3. Methodology

The pharmacy-based preventive health service framework guarantees patients get high-quality, coordinated treatment via this comprehensive approach. Pharmacists' integration into the healthcare delivery paradigm optimizes direct expenses like infrastructure and human wages while minimizing indirect costs like training and marketing. To assess the risk of chronic illness and behavioural health issues, pharmacists collect comprehensive medical histories, examine lifestyle variables and demographic information, monitor vital signs and other biometrics, and run laboratory tests. Pharmacists can better educate their patients about their health and provide individualized treatment regimens that include improvements to lifestyle and drug management when they classify these risks. Ensuring continued monitoring and revision of treatment plans via regular follow-ups and result tracking may lead to early diagnosis and prevention of illnesses.



Figure 1. Proposed CEA-PBPHS model

Figure 1 shows the proposed CEA-PBPHS model. The data are taken from the Pharmaceutical Drug Recognition Kaggle Dataset [16]. A pharmacy-based preventive health service combines many essential elements to provide patients with all-encompassing treatment. At its core, the service is patient- and community-centred; people access health care via walk-ins, appointments, and telemedicine, among other pharmacy interfaces. Next, the pharmacist consults with the patient, providing them with various health services such as evaluations of their medications, immunizations, screenings, treatment of chronic diseases, and counselling. Patients may access their medical data digitally via the Electronic Health Record (EHR) system for better administration and service continuity. The pharmacist works with other healthcare team members to facilitate smooth communication and referrals to doctors, specialists, and hospitals. An essential component of the system, health outcomes monitoring allows for the recording and assessing gains in patient health. Lastly, the services' financial components are efficiently handled by the insurance and payment processing component, which is responsible for billing, insurance claims, and payments. First, the attribute levels for all treatment options are chosen; second, the attribute levels are merged with the coefficient estimates from the discrete choice experiment to forecast the fraction of patients who will switch treatments once the medication is rescheduled. How the discrete choice experiment was processed determines the combination of these two data fragments. For instance, the subsequent expression is utilized to measure the likelihood (π) of patient j selecting treatment options 1 of I option, where the information was examined utilizing conditional logit models, y signifies the attribute level for every treatment options, and α denotes the coefficient:

$$\pi_{j1} = \frac{e^{y_{J1}\alpha}}{\sum_{i=1\ to\ I} e^{y_{ji}\alpha}} \qquad (1)$$

Many models lack a closed-form solution, except conditional and nested models. That is why it is necessary to model the choice probabilities to provide an approximate figure of the integration of choice scenarios and replies. The findings may need to be readjusted using alternative-specific constants and the percentage of patients who opted for each therapy before the schedule modification.

Let lifetime healthcare cost (IHC), survivor cost (SC), and decadent cost (DC) correspondingly. The formula then relates these costs:

$$IHC(h) = \sum_{b}^{m-1} \sum_{j} SC_j(b,h) + \sum_{j} DC_j \ (m,h) \qquad (2)$$

As inferred from equation (2), where b, h, j, m signify age, sex, disease, and age at death, correspondingly. The lifetime costs of unrelated illnesses, abbreviated as UHC, may be calculated using this bottom-up method of calculating total healthcare expenses by removing the costs of all connected diseases, denoted by Z, from Equation 1.

$$UHC(h) = \sum_{b}^{m-1} \sum_{j \in Z} SC_j(b,h) + \sum_{j \in Z} DC_j \ (m,h) \ (3)$$

The study's starting point is overall annual medical expenditures, which are decomposed into measures of healthcare costs for 107 diseases by sex, age, and healthcare providers.

The acceptance rate is the proportion of pharmacist suggestions that the doctors executed during that visit; as can be seen, the acceptance rate in equation (4) is the number of intervention cases accepted out of the total number of cases that required interventions.

$$Acceptance\ Ratio = \frac{No.of\ intervention\ cases\ accpeted}{Overall\ number\ of\ cases\ requiring\ interventions} \times 100 \quad (4)$$

The mean drug expenditures reflected the total medications used in the CCU as measured by the pharmacy department. The pharmaceutical company's computer database was mined for drug price information. Equation 5 was used to compute the mean medication expenses per admission:

$$Mean\ drug\ costs\ per\ admission\ = \frac{mean\ drug\ costs\ per\ study\ period\ time}{number\ of\ admissions\ in\ period} \ (5)$$

In the two intervention periods, if clinical pharmacy services had been available, it was estimated that mean medication expenditures would have risen by 5%.



Figure 2. Health Risk Assessment Model

Figure 2 shows the health risk assessment. More administrative burdens and unnecessary testing may be reduced via telehealth platforms and Electronic Health Record (EHR) systems. Quality-Adjusted Life Years (QALYs) are a measure of health outcomes. When chronic diseases are better managed, immunization rates are higher, and diseases are detected early, there are fewer hospital readmissions and trips to the emergency department. Compared to conventional primary care, pharmacy-based treatments provide more QALYs at a cheaper cost, according to the Incremental Cost-Effectiveness Ratio (ICER). This integration proves that pharmacy-based health services are the most cost-effective form of healthcare delivery, increasing patient satisfaction and treatment plan adherence while decreasing healthcare costs. Because of their preventative nature, pharmacy-based HRAs are an essential part of healthcare delivery systems that are both efficient and successful. They enhance patient participation and health outcomes while lowering healthcare costs by avoiding serious illnesses requiring more costly treatments. Hence, this study proposed a Cost-Effectiveness Analysis of Pharmacy-based Preventive Health Services (CEA-PBPHS) model for real-time health risk

assessment. The suggested CEA-PBPHS model increases the health risk assessment ratio, cost-effectiveness ratio and personalized health service ratio compared to other existing models.

4. Results and discussion

The data are taken from the Pharmaceutical Drug Recognition Kaggle Dataset [16]. Patient safety relies on accurate prescription issues, yet pharmaceutical mistakes are the leading cause of risk in healthcare. Human factors like exhaustion and lack of expertise most often cause errors with drugs. One type of lead error that doctors and pharmacists often make is look-alike and sound-alike (LASA). Renaming medicines and their packaging is an effective strategy to reduce the occurrence of LASA. A computerized detection system was developed to identify and avoid LASA errors after researchers reviewed medical records and used mathematical techniques to find problematic drug name combinations.

Health Risk Assessment Ratio

Health risk assessments (HRAs) evaluate possible medical risks and lifestyle variables affecting a patient's well-being. Employers, health plan providers, and healthcare professionals often use them to collect data on factors like demographics, present health status, family medical history, and lifestyle habits. Enrollment in the experiment was open to all adult pharmacy patients who were part of the partnering health plan and who had participated in the drugstore's programs for medication synchronization or adherence packaging. The pharmacy's documentation platform was used to compile the HRA findings. Time used to complete the HRA and other data points discovered by the HRA, such as new service offers (such as immunizations and smoking cessation), were also documented. The findings were described using descriptive statistics. Figure 3 shows the health risk assessment ratio.

Figure 3. Health Risk Assessment Ratio.

Cost Effectiveness Ratio

Regardless of the large variation in costs across different categories, every study consistently found that, in certain situations, treatment provided by pharmacists was more effective and cost-efficient than other options. According to research, one of the most important ways to improve the terrible situation regarding avoiding and managing complications of diabetes is to provide information and assistance for self-management of the disease. Reduced use of emergency rooms, hospitalizations, and readmissions demonstrates cost-effectiveness while improving health outcomes and patient satisfaction. This research set intended to compare the cost-effectiveness of pharmacist-assisted diabetic treatment to that of conventional care by methodically examining the input-output connection of pharmaceutical care and drawing conclusions about its economic benefits. Figure 4 shows the cost-effectiveness ratio.



Figure 4. Cost-effectiveness Ratio.

Personalized Health Service Ratio

The prediction performance of HRA models was examined using machine learning techniques, with and without laboratory data. The significance of the model characteristics was investigated to acquire insights that may be used to build personalized health management recommendations. Whether the models were trained with or without laboratory data, the research found that models using demographic, family history, lifestyle, and personal health device data performed similarly in prediction. More importantly for the development of health recommendations, the models recognized the qualities that could not be obtained from laboratory data, emphasizing changeable lifestyle variables. As a result, P4 medication may be more widely used, as healthy people may have greater access to personalized health management. Figure 5 shows the personalized health service ratio.



Figure 5. Personalized Health Service Ratio

Many medications have similar appearances, pharmaceuticals are sometimes very little, and there are a great deal of drugs that need to be recognized. The constraints of current identification solutions are not yet fully addressed. Pharmaceutical drugs from ten distinct classifications are included in the collection. The collection has almost 9,500 labelled images, including the validation images. Each labelled class has a distinct folder, and every image is associated with a certain pharmaceutical category. The results of the tests include 4,500 images of different types of drugs.

5. Conclusion and future scope

This study presents a Cost-Effectiveness Analysis of Pharmacy-based Preventive Health Services (CEA-PBPHS) model for real-time health risk assessment. New potential for pharmacy services that enhance patient care and practice sustainability might arise from the data gathered via HRAs. In addition to housing a resident in community pharmacy practice and acting as a clerkship site for a nearby pharmacy school, the pharmacy also featured space specifically reserved for patient care activities. Screenings for the stroke prevention program took place in one of three well-appointed senior

housing complexes in the same neighbourhood. With primary care already under a lot of pressure, pharmacists may help alleviate some of that burden by actively seeking out patients with undetected disorders, providing them with counselling and referrals, and assisting those at risk to slow or stop the advancement of their diseases. In general, the risk assessment is well-received by patients, and the participating pharmacists are passionate about the service; thus, it should continue. The community pharmacy was seen as easily accessible and as having the potential to reduce the bar for risk assessment. Meanwhile, the service's manageability proved its viability in real-world scenarios. The experimental outcomes demonstrate that the suggested CEA-PBPHS model increases the health risk assessment ratio by 98.9%, the personalized health service ratio by 97.5% and the cost-effectiveness analysis ratio by 98.3% compared to other existing models.

Reference

[1] Jacob, V., Reynolds, J. A., Chattopadhyay, S. K., Hopkins, D. P., Therrien, N. L., Jones, C. D., ... & Community Preventive Services Task Force. (2022). Pharmacist interventions for medication adherence: Community guide economic reviews for cardiovascular disease. *American journal of preventive medicine*, *62*(3), e202-e222.

[2] Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. *Pharmacy Practice (Granada)*, *19*(1).

[3] S. Neelima, Manoj Govindaraj, Dr.K. Subramani, Ahmed ALkhayyat, & Dr. Chippy Mohan. (2024). Factors Influencing Data Utilization and Performance of Health Management Information Systems: A Case Study. *Indian Journal of Information Sources and Services*, *14*(2), 146–152. https://doi.org/10.51983/ijiss-2024.14.2.21

[4] Rondeaux, S., Braeckman, T., Beckwé, M., Biset, N., Maesschalck, J., Duquet, N., ... & De Vriese, C. (2022). Diabetes and cardiovascular diseases risk assessment in community pharmacies: an implementation study. *International Journal of Environmental Research and Public Health*, *19*(14), 8699.

[5] Arunmanakul, P., Chaiyakunapruk, N., Phrommintikul, A., Ruengorn, C., & Permsuwan, U. (2022). Cost-effectiveness analysis of pharmacist interventions in patients with heart failure in Thailand. *Journal of the American Pharmacists Association*, *62*(1), 71-78.

[6] Kodric, Z., Vrhovec, S., & Jelovcan, L. (2021). Securing edge-enabled smart healthcare systems with blockchain: A systematic literature review. *Journal of Internet Services and Information Security*, *11*(4), 19-32.

[7] Zhu, J., Zhou, Y., & Wang, G. (2024). Cost-Effectiveness of Pharmacist Care in Diabetes Management: A Systematic Review. *Diabetes Therapy*, *15*(1), 61-76.

[8] RIKMASARI, Y., KRISTINA, S. A., ANDAYANI, T. M., & ENDARTI, D. (2021). An Economic Evaluation of Pharmacist'Intervention to Improve Blood Pressure Control: A Systematic Review. *International Journal of Pharmaceutical Research (09752366)*, *13*(2).

[9] Ahmad, A.S., Ahed, A., Al-smadi, M.K., & Al-smadi, A.M. (2024). Smart Medical Application of Deep Learning (MUNet) for Detection of COVID-19 from Chest Images. Journal of Wireless Mobile Networks, Ubiquitous Computing, and Dependable Applications (JoWUA), 15(1), 133-153.

[10] Husain, M. J., Haider, M. S., Tarannum, R., Jubayer, S., Bhuiyan, M. R., Kostova, D., ... & Choudhury, S. R. (2022). Cost of primary care approaches for hypertension management and risk-based cardiovascular disease prevention in Bangladesh: a HEARTS costing tool application. *BMJ open*, *12*(6), e061467.

[11] Kutlu, Y., & Camgözlü, Y. (2021). Detection of coronavirus disease (COVID-19) from X-ray images using deep convolutional neural networks. *Natural and Engineering Sciences*, *6*(1), 60-74.

[12] Jalkanen, K., Aarnio, E., Lavikainen, P., Lindström, J., Peltonen, M., Laatikainen, T., & Martikainen, J. (2021). Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis. *BMC Health Services Research*, *21*, 1-11.

[13] Stämpfli, D., Winkler, B. A., Vilei, S. B., & Burden, A. M. (2022). Assessment of minor health disorders with decision tree-based triage in community pharmacies. *Research in Social and Administrative Pharmacy*, *18*(5), 2867-2873.

[14] Tesfaye, W., Krass, I., Sud, K., Johnson, D. W., Van, C., Versace, V. L., ... & Castelino, R. L. (2023). Impact of a pharmacy-led screening and intervention in people at risk of or living with chronic kidney disease in a primary care setting: a cluster randomized trial protocol. *BMJ open*, *13*(12), e079110.

[15] Lilly, R., Dang, L., Frangello, J., Roque, D., & Liu, Y. (2024). Impact of pharmacist-led vaccine assessment and

patient counseling on unmet vaccination needs in the community pharmacy setting. *JAPhA Practice Innovations*, *1*(2), 100004.

[16] https://www.kaggle.com/datasets/gauravduttakiit/pharmaceutical-drug-recognition

[17] Thooyamani K.P., et.al Dynamic peer-to-peer distributed document clustering and summarization, World Applied Sciences Journal, V-29, I-14, PP:241-247, 2014.

[18] Schultz, B. G., Tilton, J., Jun, J., Scott-Horton, T., Quach, D., & Touchette, D. R. (2021). Cost-effectiveness analysis of a pharmacist-led medication therapy management program: hypertension management. *Value in Health*, *24*(4), 522-529.

[19] Rosli, M. R., Wu, D. B. C., Neoh, C. F., & Karuppannan, M. (2021). Economic evaluation of home medication review by community pharmacists (HMR-CP) for patients with type 2 diabetes mellitus (T2DM). *Journal of Medical Economics*, *24*(1), 730-740.

[20] Chua, G. N., Bond, C., Porteous, T., & Ryan, M. (2022). Will the public engage with new pharmacy roles? Assessing future uptake of a community pharmacy health check using a discrete choice experiment. *The Patient-Patient-Centered Outcomes Research*, *15*(4), 473-483.

[21] Phimarn, W., Saramunee, K., Leelathanalerk, A., Srimongkon, P., Chanasopon, S., Phumart, P., ... & Babar, Z. U. D. (2023). Economic evaluation of pharmacy services: a systematic review of the literature (2016–2020). *International Journal of Clinical Pharmacy*, *45*(6), 1326-1348.